BioAlliance Pharma presents research results for a new cancer therapy agent at the 15th congress of the European Society of Gene and Cell Therapy, Rotterdam, October 27-30.
BioAlliance Pharma SA, has announced the first promising in vivo and in vitro results for its plasmid AMEP™. The anti-angiogenic and antiproliferative properties of this innovative product (BA 015 program) were presented at the 15th congress of the European Society of Gene and Cell Therapy (ESGCT), Rotterdam (Netherlands), October 27-30.
BioAlliance Pharma has also invested in a program to identify and develop new therapeutic targets in the field of oncology, especially those involved in resistance and tumoral invasion. Its new drug candidate, AMEP™ or plasmid AMEP™, which codes for an anti-invasive peptide, is the first result of this program.
AMEP™ binds to cellular receptors, integrins, which are present on the endothelial cells of neovessels and on some tumoral cells. Its targets are two major integrins, anb3 (alpha-v-beta-3) and a5b1 (alpha-5-beta-1), involved in angiogenic and metastatic processes. The in vitro research results presented at ESCGT show that AMEP™ inhibits both proliferation and invasion of endothelial cells that cause the formation of neovessels. It also inhibits the proliferation and migration of human melanoma cells.
The in vivo research results were achieved with the AMEP™ plasmid on an invasive melanoma model using intratumoral electrotransfer. The effect of a single dose gives more than 80 per cent inhibition of tumoral growth. With repeated doses, there is a 97 per cent inhibition of tumoral growth and in 40 per cent of cases complete and lasting (more than 80 days) regression of the tumors.
Specialty pharmaceutical company focuses on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance. The company concluded two strategic partnerships in 2007 to sell its Loramyc® product in Europe and in the US. BioAlliance Pharma has just announced the launch of Loramyc® on the French market.